No kidding, Kalydeco costs $294,000 per patient per year. Reminds me of DNDN, spiked when they came out with Provenge at something like 92,000 per year. It went over 50.00 per share now trading at 4.33.
It did so in AH trading. The volume at ths price does not even warrant the capitalization. it is an oberbought AH trade. If investors dont take profit tomorrow, I will simply cease trading. I think we have all seen this before. It may rsie further, because people are stupid, but it does not warrant such a capitalization. No way, I am short at about $80 on average. And my position? Tiny.